- Home
- NJR vs PCVX Comparison
NJR vs PCVX Comparison
Compare NJR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NJR | PCVX |
|---|---|---|
| Founded | 1922 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.1B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NJR | PCVX |
|---|---|---|
| Price | $55.23 | $59.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $51.80 | ★ $98.33 |
| AVG Volume (30 Days) | 478.9K | ★ 1.2M |
| Earning Date | 05-04-2026 | 05-27-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | ★ 14.04 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $1,351,305,000.00 | N/A |
| Revenue This Year | $11.42 | N/A |
| Revenue Next Year | $2.12 | N/A |
| P/E Ratio | $45.63 | ★ N/A |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $43.46 | $28.09 |
| 52 Week High | $55.49 | $76.61 |
Technical Indicators
Market Signals| Indicator | NJR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 66.65 | 56.52 |
| Support Level | $44.41 | $42.30 |
| Resistance Level | $54.70 | $65.00 |
| Average True Range (ATR) | 0.97 | 3.00 |
| MACD | -0.04 | -0.17 |
| Stochastic Oscillator | 67.35 | 51.85 |
Price Performance
Historical ComparisonAbout NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.